Press releases
GeNeuro Reports 2021 Half-Year Results and Provides Corporate Update
Geneva, Switzerland, September 29, 2021 at 7:00pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today reported its half-year financial results for the period ending June 30, 2021 and provided a corporate update.
https://geneuro.ch/data/news/GeNeuro-PR-1H2021-Results-ENG-vf.pdf
GeNeuro and Northwestern University enter into a research collaboration on HERV-W ENV in long-haul COVID
Geneva, Switzerland, September 24, 2021, 8:00am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis, announces today that it has entered into a research agreement with Northwestern University to further investigate the relationship between HERV-W ENV (W-ENV) and long-COVID neuropsychiatric syndromes.
https://geneuro.ch/data/news/2021.09.24-GN-PR-NW-agreement-ENG.pdf
GeNeuro announces that a first patient having finished the ProTEct-MS study at the Karolinska Institutet’s Academic Specialist Center has entered the study extension
Geneva, Switzerland, September 21, 2021 – 6:30 pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced that a first patient having completed its ProTEct-MS study at Karolinska Institutet’s Academic Specialist Center (ASC) in Stockholm, which tests temelimab at monthly doses of 18, 36 and 54 mg/kg in MS patients, has entered the ProTEct-MS extension
https://geneuro.ch/data/news/GeNeuro-MS-Study-extension-announcement-ENG.pdf
GeNeuro: financial information and business update for the second quarter 2021
Geneva, Switzerland, July 23, 2021, 8:00am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today reported on its 2021 second quarter cash position and issued a business update.
GeNeuro announces the publication in Multiple Sclerosis of results from CHANGE-MS and ANGEL-MS studies
Geneva, Switzerland, July 15, 2021 – 08:00am CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical developing new treatments for neurodegenerative diseases, such as multiple sclerosis (MS), today announced publication in Multiple Sclerosis of the safety and efficacy results from its temelimab CHANGE-MS and ANGEL-MS clinical studies.
https://geneuro.ch/data/news/GeNeuro-PR-MSJournal-publication-EN.pdf
GeNeuro: successful €6 million private placement
Geneva, Switzerland, July 13, 2021 – 08:00 CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (“MS”), today announced the successful completion of a €6.0 million capital increase with cancellation of the preferential subscription rights through an international private placement only to certain qualified and institutional investors of 1,730,458 new ordinary bearer shares of GeNeuro with a par value of CHF 0.05 each (the “New Shares” and the “Offering”, respectively).
https://geneuro.ch/data/news/2021-07-13-GeNeuro-Closes-Financing-ENG.pdf